Windtree Therapeutics (WINT) Receiving Positive News Coverage, Accern Reports
Media headlines about Windtree Therapeutics (NASDAQ:WINT) have trended positive this week, Accern reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Windtree Therapeutics earned a news impact score of 0.32 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.1051871406382 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
WINT has been the subject of several recent research reports. Stifel Nicolaus lowered shares of Windtree Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 30th. Zacks Investment Research upgraded shares of Windtree Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research report on Wednesday, August 30th.
Windtree Therapeutics (NASDAQ WINT) remained flat at $0.20 during midday trading on Monday. The company’s stock had a trading volume of 7,260 shares. The firm’s market cap is $2.80 million. Windtree Therapeutics has a 1-year low of $0.18 and a 1-year high of $3.50. The firm’s 50 day moving average price is $0.21 and its 200-day moving average price is $0.75.
Windtree Therapeutics (NASDAQ:WINT) last announced its quarterly earnings data on Monday, August 21st. The biotechnology company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.23. The firm had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.40 million. On average, equities analysts anticipate that Windtree Therapeutics will post ($2.46) EPS for the current fiscal year.
About Windtree Therapeutics
Windtree Therapeutics, Inc, formerly Discovery Laboratories, Inc, is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment.
Receive News & Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.